Swedish Orphan Biovitrum AB (publ) (SWOBY)
Company Info
Highlights
$10.48B
$0.60
25.42
1.61
$26.24B
$20.41B
$12.20 - $17.20
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Swedish Orphan Biovitrum AB (publ) (SWOBY) returned 19.61% year-to-date (YTD) and 12.55% over the past 12 months.
SWOBY
19.61%
1.67%
8.73%
12.55%
N/A
N/A
N/A
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of SWOBY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 21.96% | -6.30% | -3.72% | 9.07% | -0.33% | 19.61% | |||||||
| 2024 | 1.52% | -9.66% | 4.58% | 5.85% | 1.12% | 0.22% | -1.14% | 15.83% | 5.14% | -9.48% | -5.24% | -9.09% | -3.41% |
| 2023 | -91.10% | 2.32% | -56.25% | 76.32% | 27.01% | -0.24% | -19.76% | 24.78% | 5.47% | -90.60% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of SWOBY is 63, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Swedish Orphan Biovitrum AB (publ) (SWOBY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Swedish Orphan Biovitrum AB (publ) provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2024 | 2023 |
|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.50 |
Dividend yield | 0.00% | 0.00% | 3.78% |
Monthly Dividends
The table displays the monthly dividend distributions for Swedish Orphan Biovitrum AB (publ). The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.50 | $0.00 | $0.00 | $0.00 | $0.50 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Swedish Orphan Biovitrum AB (publ). A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Swedish Orphan Biovitrum AB (publ) was 96.02%, occurring on Jun 30, 2023. The portfolio has not yet recovered.
The current Swedish Orphan Biovitrum AB (publ) drawdown is 89.15%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.02% | Apr 5, 2023 | 10 | Jun 30, 2023 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Swedish Orphan Biovitrum AB (publ) over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Swedish Orphan Biovitrum AB (publ), comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Swedish Orphan Biovitrum AB (publ) is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SWOBY, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SWOBY has a P/E ratio of 25.4. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for SWOBY compared to other companies in the Drug Manufacturers - Specialty & Generic industry. SWOBY currently has a PEG ratio of 1.6. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SWOBY relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SWOBY has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SWOBY in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SWOBY has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |